-+ 0.00%
-+ 0.00%
-+ 0.00%

Entrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases

PUBT·08/05/2026 12:19:51
Listen to the news
Entrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases
  • Entrada Therapeutics outlined four clinical data catalysts in 2026 across Duchenne muscular dystrophy and partnered myotonic dystrophy type 1.
  • ENTR-601-44 Phase 1/2 Cohort 1 at 6 mg/kg showed no serious adverse events or discontinuations; renal markers stayed within normal range.
  • Cohort 1 showed statistically significant improvement versus placebo in Time to Rise of 2.4 seconds, Time to Rise Velocity of 0.09 rises/second.
  • ENTR-601-44 Cohort 1 open-label function and safety data expected by year-end 2026; Cohort 2 at 12 mg/kg data expected in Q1 2027.
  • ENTR-601-45 Cohort 1 data expected in October 2026; Vertex plans to share VX-670 Phase 1/2 multiple-ascending-dose results in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.